DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

Information source: Nihon Pharmaceutical Co., Ltd
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: NPO-11 (Drug); NPO-11 (Drug); NPO-11 (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Nihon Pharmaceutical Co., Ltd

Summary

The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult men. The safety will be evaluated based on adverse events and adverse drug reactions (ADRs) observed with NPO-11 + scopolamine butylbromide or glucagon, and following additional administration of NPO-11. The efficacy will be evaluated based on changes in the frequency of gastric peristalsis classification after the initial dose and the additional dose, and on the presence or absence of gastric peristalsis at each evaluation point.

Clinical Details

Official title: Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men During Endoscopy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: [Safety] (Evaluation by investigator or subinvestigator) Adverse events and ADRs observed between administration and 7 ± 3 days after administration

Secondary outcome: [Efficacy] (Central evaluation by independent evaluator) (1) Change in the frequency of gastric peristalsis classification (2) Presence or absence of gastric peristalsis at each evaluation point

Eligibility

Minimum age: 35 Years. Maximum age: 65 Years. Gender(s): Male.

Criteria:

Inclusion Criteria: Healthy adult male volunteers who meet all the following criteria will be enrolled in the study. Subjects have to provide written informed consent for voluntary participation in the study. 1. Volunteers who are in good health as confirmed by the investigator or subinvestigator 2. Volunteers (age from 35 to less than 65 years old at the time of consent) Exclusion Criteria: Volunteers who meet any of the following criteria will be excluded from the study. 1. Volunteers with any clinically significant symptoms, physical findings or laboratory values at screening visit which are considered unsuitable for participation in the study in the investigator's or subinvestigator's opinion 2. Volunteers with a history of surgery in the upper gastrointestinal tract 3. Volunteers with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil) 4. Volunteers with a history of shock or hypersensitivity to scopolamine butylbromide, glucagon, lidocaine hydrochloride or heparin sodium 5. Volunteers who are contraindicated for administration of scopolamine butylbromide or glucagon in the investigator's or subinvestigator's opinion based on health interview 6. Volunteers who have been exposed to NPO-11 7. Volunteers who have received other investigational drugs within four months before consent or who are participating in other clinical studies 8. Volunteers otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion

Locations and Contacts

Tokyo, Japan
Additional Information

Starting date: August 2008
Last updated: November 8, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017